Jorma J. Isola

Q: What Schools Are Affiliated With Jorma J. Isola

Jorma J. Isola is affiliated with the following schools: Tampere University, University of Helsinki

Jorma J. Isola's AcademicInfluence.com Rankings

Jorma J. Isola

Biology

#9469

World Rank

#12680

Historical Rank

Genetics

#969

World Rank

#1065

Historical Rank

Molecular Biology

#1300

World Rank

#1327

Historical Rank

Biochemistry

#1447

World Rank

#1572

Historical Rank

biology Degrees

Download Badge

Biology

Jorma J. Isola's Degrees

PhD Molecular Biology University of Helsinki
Masters Biochemistry University of Helsinki

Why Is Jorma J. Isola Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jorma J. Isola's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

In vivo amplification of the androgen receptor gene and progression of human prostate cancer (1995) (1521)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. (2006) (1138)
Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors (1994) (1073)
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. (2002) (820)
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. (1997) (780)
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. (2005) (700)
Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. (1995) (543)
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity (2007) (535)
Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. (2005) (469)
ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 (2010) (465)
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. (2009) (455)
Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. (1997) (433)
Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. (1994) (428)
Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. (2000) (409)
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. (1997) (407)
Molecular cytogenetics of primary breast cancer by CGH (1998) (398)
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. (2000) (391)
Trastuzumab emtansine: mechanisms of action and drug resistance (2014) (371)
Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. (1992) (369)
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair (2008) (369)
Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer (1991) (361)
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. (1996) (351)
Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. (2000) (347)
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. (1995) (331)
Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. (1992) (328)
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. (1992) (323)
Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. (1996) (314)
Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. (1998) (314)
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. (2002) (290)
Estrogen Receptor β Is Coexpressed with ERα and PR and Associated with Nodal Status, Grade, and Proliferation Rate in Breast Cancer (2000) (279)
Current Perspectives on HER2 Testing: A Review of National Testing Guidelines (2003) (278)
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. (2004) (257)
Cytogenetic Alterations and Cytokeratin Expression Patterns in Breast Cancer: Integrating a New Model of Breast Differentiation into Cytogenetic Pathways of Breast Carcinogenesis (2002) (256)
Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. (2006) (254)
CIP2A Is Associated with Human Breast Cancer Aggressivity (2009) (237)
Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. (2003) (222)
Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance (2007) (220)
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study (2011) (209)
Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. (2001) (208)
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors (2005) (201)
Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. (1996) (198)
Risk for distant recurrence of breast cancer detected by mammography screening or other methods. (2004) (197)
Evaluation of cell proliferation in breast carcinoma. Comparison of Ki‐67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count (1990) (193)
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo (2011) (190)
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. (2005) (187)
Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization (2004) (182)
Characterization of topoisomerase IIα gene amplification and deletion in breast cancer (1999) (177)
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in Gliomas (2006) (176)
Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study (2001) (175)
Prognostication of astrocytoma patient survival by Ki‐67 (MIB‐1), PCNA, and S‐phase fraction using archival paraffin‐embedded samples (1994) (173)
Genetic alterations in lobular breast cancer by comparative genomic hybridization (1997) (171)
Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. (2002) (169)
Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. (2003) (166)
Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors (1993) (165)
Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. (2004) (163)
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. (2011) (161)
Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. (1998) (154)
Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. (1998) (152)
Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. (2005) (152)
Optimizing DOP‐PCR for universal amplification of small DNA samples in comparative genomic hybridization (1997) (151)
Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-Negative Breast Carcinoma (2007) (147)
Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. (1995) (147)
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma (2006) (144)
Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. (1999) (144)
Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. (2007) (141)
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. (2011) (141)
Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. (1994) (140)
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers (2007) (140)
Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. (2000) (137)
Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. (1996) (132)
HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel (2004) (131)
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping (2000) (127)
Basoluminal Carcinoma: A New Biologically and Prognostically Distinct Entity Between Basal and Luminal Breast Cancer (2006) (127)
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. (2009) (124)
ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. (2004) (120)
Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. (2003) (118)
Association of Wwox with ErbB4 in breast cancer. (2007) (115)
The effect of age and density of the breast on the sensitivity of breast cancer diagnostic by mammography and ultasonography (2001) (114)
Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. (1997) (113)
Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression (2006) (113)
Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening (2008) (112)
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. (2001) (112)
Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. (1993) (111)
Patterns of chromosomal imbalances in parathyroid carcinomas. (2000) (110)
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer (2016) (107)
Colocalization of peptide and glucocorticoid receptor immunoreactivities in rat central amygdaloid nucleus. (1992) (107)
Elevated erbB‐2 oncoprotein levels in preoperative and follow‐up serum samples define an aggressive disease course in patients with breast cancer (1994) (106)
MYB oncogene amplification in hereditary BRCA1 breast cancer. (2000) (104)
Mechanical loading regulates tenascin-C expression in the osteotendinous junction. (1999) (104)
Localization of the glucocorticoid receptor in testis and accessory sexual organs of male rat (1993) (104)
Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence—first results of an inter‐ethnic breast cancer study (2004) (103)
A digital atlas of breast histopathology: an application of web based virtual microscopy (2004) (102)
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. (2010) (101)
Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. (2003) (101)
Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. (1992) (99)
Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. (1999) (98)
Comparison of different immunohistochemical methods in the assessment of angiogenesis: lack of prognostic value in a group of 77 selected node-negative breast carcinomas. (1995) (97)
Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. (2002) (95)
EZH2, Ki‐67 and MCM7 are prognostic markers in prostatectomy treated patients (2008) (92)
Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and dna flow cytometry (1990) (91)
The calcium-binding protein S100P in normal and malignant human tissues (2008) (91)
Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. (1993) (90)
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. (2006) (90)
Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. (1994) (87)
Effect of age on the survival of breast cancer patients. (1997) (87)
Haplo-insufficiency of BRCA1 in sporadic breast cancer. (2003) (87)
Web-based virtual microscopy in teaching and standardizing Gleason grading. (2005) (86)
Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors (2010) (84)
Overexpression of p53 and long-term survival in colon carcinoma. (1994) (84)
Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer. (1993) (82)
Steroid receptors and Ki‐67 reactivity in ovarian cancer and in normal ovary: Correlation with dna flow cytometry, biochemical receptor assay, and patient survival (1990) (81)
Expression of ERα and ERβ in prostate cancer (2003) (80)
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer (2011) (79)
Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas (2002) (76)
Evaluation of HER-2/NEU Protein Expression in Breast Cancer by Immunohistochemistry: An Interlaboratory Study Assessing the Reproducibility of HER-2/NEU Testing (2002) (73)
Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. (1998) (71)
Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? (2003) (71)
Genetic alterations in ERBB2-amplified breast carcinomas. (1999) (70)
Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. (1997) (69)
ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistry (2012) (67)
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer (2008) (65)
Breast cancer outcome prediction with tumour tissue images and machine learning (2019) (65)
Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. (1991) (65)
Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping (2000) (65)
The Application of JPEG2000 in Virtual Microscopy (2009) (65)
Elevated levels of StAR-related lipid transfer protein 3 alter cholesterol balance and adhesiveness of breast cancer cells: potential mechanisms contributing to progression of HER2-positive breast cancers. (2015) (63)
A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. (2009) (63)
Aggressiveness of screen-detected breast cancers (1995) (62)
Aurora-A gene is frequently amplified in basal-like breast cancer. (2010) (61)
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. (2007) (59)
Preservation of nucleic acids and tissue morphology in paraffin-embedded clinical samples: comparison of five molecular fixatives (2013) (59)
Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping. (2001) (59)
Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma. (2011) (58)
Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. (2001) (58)
Down-Regulated Xanthine Oxidoreductase Is a Feature of Aggressive Breast Cancer (2005) (57)
Characterization of a Novel Breast Carcinoma Xenograft and Cell Line Derived from a BRCA1 Germ-Line Mutation Carrier (2003) (57)
Stromal cell cathepsin D expression and long-term survival in breast cancer. (1995) (55)
Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy. (1991) (54)
Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. (2002) (54)
Long-term prognosis of breast cancer detected by mammography screening or other methods (2011) (54)
Amplification of c-myc Oncogene by Chromogenic and Fluorescence In Situ Hybridization in Archival Breast Cancer Tissue Array Samples (2001) (53)
Dual‐colour chromogenic in situ hybridization for testing of HER‐2 oncogene amplification in archival breast tumours (2006) (52)
Grading of Neuroendocrine Tumors With Ki-67 Requires High-quality Assessment Practices (2012) (51)
Exogenous sex hormone use and risk of meningioma: a population-based case–control study in Finland (2010) (51)
Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. (1995) (51)
Linking Whole-Slide Microscope Images with DICOM by Using JPEG2000 Interactive Protocol (2009) (50)
Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. (2008) (50)
Epithelial Syndecan-1 Expression Is Associated with Stage and Grade in Colorectal Cancer (2005) (50)
Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone‐refractory recurrent prostate cancer (1997) (49)
Chromosomal aberrations in breast cancer: A comparison between cytogenetics and comparative genomic hybridization (1999) (47)
Intratumor variation in cell proliferation in breast carcinoma as determined by antiproliferating cell nuclear antigen monoclonal antibody and automated image analysis. (1993) (47)
Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation (2018) (46)
Web-Based Virtual Microscopy for Parasitology: A Novel Tool for Education and Quality Assurance (2008) (45)
Amplification of c-myc by Fluorescence In Situ Hybridization in a Population-Based Breast Cancer Tissue Array (2001) (45)
Mapping the amplification of EIF3S3 in breast and prostate cancer (2000) (45)
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. (2007) (43)
Immunocytochemical localization of progesterone receptor in the chick ovary. (1987) (43)
Associations of ErbB2, β1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines (2005) (43)
High topoisomerase IIα expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas (2000) (43)
Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival (2006) (42)
Detection of germline BRCA1 mutations in breast cancer patients by quantitative messenger RNA in situ hybridization. (1996) (42)
P53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. (1997) (42)
Development of progestin-specific response in the chicken oviduct. (1989) (42)
Accumulation of genetic changes is associated with poor prognosis in grade II astrocytomas. (1997) (41)
Comparison of three quantitation methods for PCNA immunostaining: Applicability and relation to survival in 83 astrocytic neoplasms (1993) (41)
Immunocytochemical detection of estrogen and progesterone receptors in 124 human breast cancers. (1988) (40)
CDKN2/p16 Predicts Survival in Oligodendrogliomas: Comparison with Astrocytomas (1999) (40)
Morphology and histochemistry of the myotendineal junction of the rat calf muscles. Histochemical, immunohistochemical and electron-microscopic study. (1991) (39)
Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer. (2002) (39)
Chromosome arm‐specific multicolor FISH (2001) (39)
A Novel Anti-HER2 Antibody–Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine (2019) (39)
Virtual microscopy (2004) (38)
Cancer incidence in families with multiple glioma patients (2002) (38)
Overall and worst gleason scores are equally good predictors of prostate cancer progression (2011) (38)
Expression of ERalpha and ERbeta in prostate cancer. (2003) (38)
Molecular cytogenetics of human breast cancer. (1994) (38)
The visibility of cancer on earlier mammograms in a population-based screening programme. (1999) (37)
A web-based system for individualised survival estimation in breast cancer (2003) (36)
Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry (2016) (36)
Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ‐line mutation carriers (2000) (35)
Prognostic variables in predicting pregnancy. A prospective follow up study of 907 couples with an infertility problem. (1994) (35)
Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma (2000) (35)
Atrophy and regeneration of rat calf muscles cause reversible changes in the number of nucleolar organizer regions. Evidence that also in nonproliferating cells the number of NORs is a marker of protein synthesis activity. (1993) (34)
Chemical castration and anti‐androgens induce differential gene expression in prostate cancer (2012) (34)
Vitamin D Receptor Alleles and Bone's Response to Physical Activity (1998) (33)
Genetic aberrations in pediatric acute lymphoblastic leukemia by comparative genomic hybridization. (1997) (32)
HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005 (2009) (32)
The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues. (2013) (31)
Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry (2016) (31)
Analysis of p53 Tumor Suppressor Gene in Families with Multiple Glioma Patients (2001) (31)
Deep learning identifies morphological features in breast cancer predictive of cancer ERBB2 status and trastuzumab treatment efficacy (2021) (31)
Virtual microscopy in prostate histopathology: simultaneous viewing of biopsies stained sequentially with hematoxylin and eosin, and alpha-methylacyl-coenzyme A racemase/p63 immunohistochemistry. (2006) (31)
Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck. (2002) (31)
Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma (2009) (30)
Automated peak detection and cell cycle analysis of flow cytometric DNA histograms. (1994) (30)
ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. (2020) (29)
Very high quantitative tumor HER2 content and outcome in early breast cancer. (2011) (29)
A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals (2007) (29)
Frequent Amplification of Chromosomal Region 20 q 12-q 13 in Ovarian Cancer 1 (2000) (29)
Distribution of estrogen and progesterone receptors and steroid-regulated gene products in the chick oviduct (1990) (29)
c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. (1996) (28)
Ultrarapid Ki-67 immunostaining in frozen section interpretation of gliomas (2005) (28)
An immunocytochemical study of the progesterone receptor in rabbit ovary (1988) (28)
Sources of variation in the assessment of cell proliferation using proliferating cell nuclear antigen immunohistochemistry. (1994) (27)
Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study (2012) (27)
Cytokeratin-Supervised Deep Learning for Automatic Recognition of Epithelial Cells in Breast Cancers Stained for ER, PR, and Ki-67 (2020) (27)
Hormone replacement therapy and biological aggressiveness of breast cancer (1997) (26)
Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria. (2009) (25)
Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma (2014) (25)
Optimized JPEG 2000 Compression for Efficient Storage of Histopathological Whole-Slide Images (2018) (24)
Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas (2005) (24)
Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. (2009) (24)
Progesterone receptor in the chick bursa of fabricius: characterization and immunohistochemical localization. (1985) (24)
Generalisability of survival estimates for patients with breast cancer--a comparison across two population-based series. (2006) (24)
Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1. (2007) (24)
Chromogenic in situ hybridization in tumor pathology. (2004) (24)
Immunoelectron-microscopic localization of a proliferation-associated antigen Ki-67 in MCF-7 cells (1990) (23)
Characterization of Non-Specific Cytotoxic Cell Receptor Protein 1: A New Member of the Lectin-Type Subfamily of F-Box Proteins (2011) (23)
Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer. (2006) (23)
Colocalization of Fos‐ and Glucocorticoid Receptor‐Like Immunoreactivities in the Rat Amygdaloid Complex After Immobilization Stress (1992) (23)
L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer (2016) (22)
Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer (2012) (22)
Macromolecular composition of the myotendinous junction. (1991) (22)
Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient--fact or fallacy. (1995) (22)
Amplification of erbB 2 and erbB 2 Expression Are Superior to Estrogen Receptor Status As Risk Factors for Distant Recurrence in pT 1 N 0 M 0 Breast Cancer : A Nationwide Population-based Study 1 (2003) (22)
Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer (2016) (22)
New prognostic factors in prostatic carcinoma. (1993) (21)
A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer. (2010) (21)
A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer (2007) (21)
Proliferative activity and steroid receptors determined by immunohistochemistry in adjacent frozen sections of 102 breast carcinomas. (1989) (21)
Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. (2005) (19)
Application of bioinformatics in probe design enables detection of enteroviruses on different taxonomic levels by advanced in situ hybridization technology. (2015) (19)
The visibility of cancer on previous mammograms in retrospective review. (2001) (19)
Four‐color CGH: A new method for quality control of comparative genomic hybridization (1999) (19)
Immunoelectron microscopic localization of progesterone receptor in the chick oviduct. (1987) (17)
Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki‐67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine‐treated prostate cancer (2011) (17)
Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma. (1990) (16)
Effect of radiotherapy on the interpretation of routine follow-up mammography after conservative breast surgery: a randomized study. (1998) (16)
Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa (2001) (16)
Characterization of 10 vulvar carcinoma cell lines by karyotyping, comparative genomic hybridization and flow cytometry. (2004) (15)
Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer. (2010) (15)
Simultaneous localization of calcitonin gene-related peptide and neurotensin in rat central amygdaloid nucleus (1990) (15)
Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry (2016) (14)
Short Communication Estrogen Receptor b Is Coexpressed with ERa and PR and Associated with Nodal Status, Grade, and Proliferation Rate in Breast Cancer (2000) (13)
Chromosome 17 polysomy: a unifying hypothesis underlying benefit from adjuvant anthracyclines (2009) (13)
Serous and mucinous borderline tumors of the ovary: a clinicopathologic and DNA‐ploidy study of 102 cases (1996) (13)
Immunochemical characterization of a novel mitochondrially located protein encoded by a nuclear gene within the DFNB8/10 critical region on 21q22.3. (1997) (13)
Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer. (2001) (12)
Validity of radiological examinations of patients with breast cancer in different age groups in a population based study. (2001) (12)
L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer. (2016) (12)
Sexual maturation-associated and estrogen-induced progesterone receptor expression in the bursa of Fabricius. (1987) (12)
Characterization of the estrogen-sensitive cells expressing progesterone receptor in the bursa of Fabricius (1987) (11)
Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer (2018) (11)
Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours (2006) (11)
Inhibition of epithelial growth factor receptor signalling does not preserve epithelial barrier function after in vitro gliadin insult (2009) (11)
Anti-oestrogen stimulation of ERBB2 ectodomain shedding from BT-474 human breast cancer cells with ERBB2 gene amplification. (1996) (11)
No GIST-type c-kit gain of function mutations in neuroblastic tumours (2005) (10)
Biological aggressiveness of prostate cancer in the Finnish screening trial (2009) (10)
Quantification of Estrogen Receptor-Alpha Expression in Human Breast Carcinomas With a Miniaturized, Low-Cost Digital Microscope: A Comparison with a High-End Whole Slide-Scanner (2015) (10)
Prognostic value of cells with more than 5c DNA content in node-negative breast cancer as determined by image cytometry from tissue sections. (1993) (10)
Augmentation of progesterone receptor concentration by progesterone and estrogen treatments in the chick oviduct. (1984) (9)
Imprint cytology in immunocytochemical analysis of oestrogen and progesterone receptors of breast carcinoma. (1989) (9)
Glucocorticoid receptor‐mediated transcriptional activation of S100P gene coding for cancer‐related calcium‐binding protein (2011) (9)
Immunocytochemical detection of progesterone receptor in breast carcinoma. Comparison of two monoclonal antibodies. (1990) (9)
Evaluation of camera requirements for comparative genomic hybridization. (1996) (9)
Direct Eye Visualization of Cy5 Fluorescence for Immunocytochemistry and In Situ Hybridization (2000) (8)
Accumulation of p53 protein correlates with tumour proliferative activity in EBV positive Burkitt's lymphoma (1992) (8)
Advances in Brief Prognostic Significance of Elevated Cyclooxygenase-2 Expression in Breast Cancer 1 (2002) (8)
Quantitative Analysis of &ggr;-H2AX and p53 Nuclear Expression Levels in Ovarian and Fallopian Tube Epithelium from Risk-reducing Salpingo-Oophorectomies in BRCA1 and BRCA2 Mutation Carriers (2014) (7)
S24 Update of the FINHER trial based on 5 years of follow-up (2009) (7)
Association of Wwox with ErbB 4 in Breast Cancer (2007) (7)
Arm-specific multicolor fluorescence in situ hybridization reveals widespread chromosomal instability in glioma cell lines. (2003) (7)
Monoclonal-antibody-based noncompetitive avidin-biotin assay for lutropin in urine. (1988) (7)
High cell proliferation activity determined by DNA flow cytometry predicts poor prognosis after relapse in prostate cancer. (1994) (6)
The effect of progesterone on the localization of progesterone receptors in the nuclei of chick oviduct cells (1987) (6)
Length of prostate biopsies is not necessarily compromised by pooling multiple cores in one paraffin block: an observational study (2015) (6)
Routine dual-color immunostaining with a 3-antibody cocktail improves the detection of small cancers in prostate needle biopsies. (2011) (6)
Evaluation of a web-based system for survival estimation in breast cancer (2003) (6)
Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER 2 Gene Status in Breast Cancer (2009) (6)
Estrogen Receptor B Expression Is Associated withTamoxifen Response in ERA-Negative Breast Carcinoma (2007) (5)
Cryopreserved chronic lymphocytic leukemia cells analyzed by multicolor fluorescence in situ hybridization after optimized mitogen stimulation (2002) (5)
Oestrogen receptor content and cancer cell/stroma ratio in mammary carcinoma (1988) (4)
Immunohistochemical versus biochemical estrogen-receptor and progesterone-receptor analysis: correlation with histological parameters (2004) (4)
Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer (2016) (4)
Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk‐reducing salpingo‐oophorectomies (2015) (4)
Validation of a web-based prognostic system for breast cancer (2004) (4)
A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer. (2009) (4)
Computer-assisted image analysis of histopathological breast cancer images using step-DTOCS (2014) (3)
[Targeted cytotoxic drugs emerging for cancer therapy]. (2011) (3)
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis (2021) (3)
Correction: Web-Based Virtual Microscopy for Parasitology: A Novel Tool for Education and Quality Assurance (2008) (3)
p-53 gene mutations as a predictive marker in advanced breast cancer patients randomly treated either with doxorubicin or with docetaxel (2004) (3)
Ultrastructure and collagen composition of the myo-fascial junction in rat calf muscles. (1992) (3)
Nuclear origin of progesterone receptor of the chick oviduct cytosol (2004) (3)
14th European Congress on Digital Pathology (2019) (3)
14th European Congress on Digital Pathology (2019) (3)
14th European Congress on Digital Pathology (2019) (3)
Correlation of quantitative total HER2 expression and HER2 homodimers with histopathologic characteristics of breast cancers in the FinHer study. (2009) (3)
Fluoro-Chromogenic Labelling for Detection of MCM2 to Assess Proliferation Activity in HER2-amplified Breast Carcinomas (2018) (2)
Amplification of 20q13 locus in breast cancer: -Defining the minimal region (1994) (2)
Quantitative measurements of HER2 expression and HER2 homodimer using a novel proximity based assay: comparison with HER2 status by immunohistochemistry and chromogenic in situ hybridization in the FinHer study. (2009) (2)
Molecular Cytogenetics of Solid Tumor Progression (1996) (2)
Abstract 869: PTEN/PI3K oncogenic pathway profiling informs an in vivo synergistic therapeutic model for basal-like breast cancer. (2013) (2)
Abstract PD10-06: CXCL13 mRNA predicts Docetaxel benefit in Triple Negative tumors (2012) (2)
Immunohistochemical determination of estrogen and progesterone receptors and DNA flow cytometry in endometrial cancer (1993) (2)
Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401. (2005) (2)
Influence of endocrine status on biochemical and immunocytochemical estrogen and progesterone receptor assays in breast cancer patients (1988) (2)
Abstract P1-08-06: Low tumor CD68 mRNA content (intratumoral macrophages) is predictive for benefit from adjuvant trastuzumab in HER2-positive breast cancer: An analysis of the FinHER trial (2013) (2)
Immunocytochemical detection of progesterone receptors in human breast cancer: correlation with steroid-binding assay and histologic parameters (1988) (2)
Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis (2018) (2)
Advances in Brief MYB Oncogene Amplification in Hereditary BRCA 1 Breast Cancer 1 (2000) (2)
PDK 1 potentiates upstream lesions on the PI 3 K pathway in breast carcinoma (2009) (2)
527 POSTER Breast cancer detection in mammography screening has independent influence on survival when cancer size and biological subtype are accounted for (2007) (2)
[Clinical pathology on the verge of virtual microscopy]. (2015) (1)
831 DIFFERENCES IN GENE EXPRESSION INDUCED BY CHEMICAL CASTRATION AND ANTI-ANDROGENS IN PROSTATE CANCER (2011) (1)
Relative harms and merits of postoperative radiation following conservative surgery for low risk breast cancer (2002) (1)
Generalizability of survival estimates for patients with breast cancer — a comparison across two population-based series (2006) (1)
Computer program for correction of nonspecific binding in assays of steroid hormone receptors. (1988) (1)
Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study (2012) (1)
Clinicopathological and prognostic correlations of HER 3 expression and its degradation regulators , NEDD 4 – 1 and NRDP 1 , in primary breast cancer (2018) (1)
Morphological extraction of cancerous nucleus in the diagnostics of breast cancer (2015) (1)
Outcome and biomarker supervised deep learning for survival prediction in two multicenter breast cancer series (2022) (1)
Trastuzumab emtansine: mechanisms of action and drug resistance (2014) (1)
449 A New method for elimination of nonspesific binding in steroid receptor assays (1983) (0)
P04.78 Ultrarapid FGFR3 immunostaining for diagnosis of gliomas harboring FGFR3 gene fusions (2018) (0)
Nuclei Malignancy Analysis Based on an Adaptive Bottom-Hat Filter (2016) (0)
Hematoxylin Counterstain To Simplify Whole Slide Scanning Of Immunofluorescence Stains (2016) (0)
Genetic Alterations in ERBB 2-amplified Breast Carcinomas 1 , 2 (1999) (0)
Extent of 20Q13 amplicons in primary breast cancer and association with indicators of poor prognosis (1995) (0)
Development and evaluation of an automated, Web-based tool for quantitative assessment of fluorescence in situ hybridization (2007) (0)
Abstract 673: Exploration of tissue morphologies in breast cancer samples using unsupervised machine learning (2017) (0)
Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer (2018) (0)
Comparative genomic hybridization: Methodology and application in the analysis of genetic aberrations in human solid tumors (1994) (0)
Contents Vol. 68, 2005 (2005) (0)
Electron microscopic immunocytochemistry using the pre-embedding method (1990) (0)
' s response to reviews Title : Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer : a prospective observational study (2012) (0)
Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation (2018) (0)
Optimal Image Data Compression For Whole Slide Images (2016) (0)
Original Article The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues (2013) (0)
E-Cadherin Expression Breast (2015) (0)
Growth of Breast Cancer Cells Regulated − Cleavable ErbB 4 Isoform in Estrogen Receptor (2005) (0)
Methodological development of fluorescence in situ hybridization (1994) (0)
Koivisto, P. et al. Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am. J. Pathol. 147, 1608-1614 (1996) (0)
7 Further studies with polyclonal antibodies against the chick oviduct progesterone receptor (1985) (0)
Decreased CDKN2 expression in astrocytomas and oligodendrogliomas is associated with poor prognosis (1999) (0)
Evaluation of HER-2 protein expression in primary breast cancer (PBC) by immunohistochemistry (IHC): An interlaboratory study assessing the reproducibility of HER-2 testing (2001) (0)
Genome-wide survey of gains and losses of DNA sequences in primary prostate cancer by comparative genomic hybridization (1994) (0)
Analyzing Toposimerase II-α and HER-2/neu co-amplification seems to be of limited value in epithelial ovarian cancer (2009) (0)
64 The prognostic and predictive role of HER-2 and topoisomerase II alpha in breast cancer (BC) (2003) (0)
Trastuzumab insensitivity despite HER-2 receptor down-regulation and internalization in a novel cell line established from a Herceptinresistant breast cancer patient. (2003) (0)
Abstract P5-02-01: Comparison of ESR1, PGR, HER2 and KI67 expression by central IHC and MammaTyper® RT-qPCR kit in the FinHer trial (2015) (0)
P2-12-04: RACGAP1 mRNA Assay Outperforms Ki-67 as a Proliferation Marker in the FinHer Study Cohort. (2011) (0)
[New studies on breast cancer to predict disease outcome and clinical use of these new tests]. (1991) (0)
Digital image analysis of the tissue surface areas of site-designated and bilaterally pooled prostate biopsies. (2018) (0)
Breast Cancer Patients with Very High Tumor HER2 Expression Levels Might Not Benefit from Treatment with Trastzumab Plus Chemotherapy: A Retrospective Exploratory Analysis of the FinHer Trial. (2009) (0)
Optimizing Optical And Digital Resolution For Brightfield Whole Slide Scanning (2016) (0)
Genetic basis of human prostate cancer development and progression (1995) (0)
P1-11 Multispectral imaging for multicolor immunohistochemical and transmission in-situ hybridization (2002) (0)
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer (2016) (0)
Erratum to “Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma” [Gynecol Oncol. 120 (2011) 11–17] (2012) (0)
Estrogen and Anti-Estrogen Regulation of Amplified erbB2 Gene Expression in Human Breast Cancer Cells (1996) (0)
Serous and mucinous borderline tumors of the ovary: a clinicopathologic and DNA-ploidy study of 102 cases (1996) (0)
91047154 Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: Correlation with DNA flow cytometry, biochemical receptor assay, and patient survival (1991) (0)
[Determination of steroid receptors in breast cancer by immunohisto- chemical technics]. (1988) (0)
1471: Biological Aggressiveness of Prostate Cancer in the Finnish Screening Trial (2006) (0)
Epidermal Growth Factor Receptor (EGFR) in primary breast cancer-protein expression, but not gene copy number, gives important prognostic information in tamoxifen treated patients (2008) (0)
MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1/OCT4 levels (2022) (0)
P1-07-01: Comparison of Four HER2 Testing Methods in the Detection of HER2−Positive Breast Cancer: Results from the FinHer Study Cohort. (2011) (0)
Estrogen receptor analysis on breast cancer imprints (1998) (0)
Changes in importance of items in the social and personal life of breast cancer patients over time (1999) (0)
Subject Index Vol. 68, 2005 (2005) (0)
and Metastatic Breast Cancer in Primary α Amplification of HER-2/neu and Topoisomerase II (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jorma J. Isola?

Jorma J. Isola is affiliated with the following schools:

Jorma J. Isola's Academic­Influence.com Rankings

Jorma J. Isola's Degrees

Why Is Jorma J. Isola Influential?

Jorma J. Isola's Published Works

Published Works

What Schools Are Affiliated With Jorma J. Isola?

Jorma J. Isola's AcademicInfluence.com Rankings